Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene receives $15.3 Million from the Sale of Securities Held for Sale
information fournie par Boursorama CP 17/07/2023 à 17:45

Transgene receives $15.3 Million from the Sale of Securities Held for Sale

Strasbourg, France, July 17, 2023, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it has received $15.3 million (€ 14.0 million) as a result of the full disposal of its minority stake in a Chinese biopharmaceutical company.

Following this transaction, which completion was expected for mid-2023, Transgene reaffirms its financial visibility until early 2024.

Contacts
Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04

Media: MEDiSTRAVA Consulting
David Dible/Sylvie Berrebi
+44 (0)203 928 6900
transgene@medistrava.com

Valeurs associées

TRANSGENE
0,8300 EUR Euronext Paris -0,60%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
CAC 40
8 038,98 +0,72%
Pétrole Brent
108,15 -2,50%
SOITEC
158,9 +11,00%
NANOBIOTIX
36,6 -4,89%
TOTALENERGIES
80,71 +1,15%
Chargement...

Pages les plus populaires

L'offre BoursoBank